Drug Type Small molecule drug |
Synonyms EP-31670, EP31670, NEO 2734 |
Mechanism BET inhibitors(Bromodomain and extra terminal domain protein inhibitors), p300-CBP transcription factors inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | US | 21 Dec 2022 | |
Castration-Resistant Prostatic Cancer | Phase 1 | US | 21 Dec 2022 | |
Chronic Myelomonocytic Leukemia | Phase 1 | US | 21 Dec 2022 | |
Myelofibrosis | Phase 1 | US | 21 Dec 2022 | |
NUT midline carcinoma | Phase 1 | US | 21 Dec 2022 | |
Diffuse Large B-Cell Lymphoma | Preclinical | - | - | |
Diffuse Large B-Cell Lymphoma | Preclinical | - | Epigene Labs SASStartup | - |
Leukemia | Preclinical | - | Epigene Labs SASStartup | - |
Leukemia | Preclinical | - | - | |
Prostatic Cancer | Preclinical | - | - |